×

Register now for full access to all the content

First Name
Last Name
Company
Title
Country
Thank you for registering!
Error - something went wrong!
   

Three drug development habits to mitigate commercial risk

September 22, 2017

In today’s cost-constrained healthcare markets, winning payer reimbursement for newly approved products has become increasingly challenging. And even if a drug wins reimbursement, there are no guarantees it will succeed in the market.

However promising a product might appear, if you do not have the right evidence early on (or if you fail to recognize that the data you do have are no longer relevant to key stakeholders), risks may actually be rising as market launch nears. 

Commercial risk is so multifaceted that developers need a multifaceted strategy to cope with it, incorporating evidence generation, gated reviews and market analysis. While this will require more work, the return on the investment is high.

Previous Flipbook
How to Build a Sturdy Global Value Platform for Success in a Value-based World
How to Build a Sturdy Global Value Platform for Success in a Value-based World

Read this article to find out how PAREXEL can help you with your product value story!

Next Flipbook
Dynamic Reimbursement Working In Practice? Cancer Drugs Fund Reforms In The UK
Dynamic Reimbursement Working In Practice? Cancer Drugs Fund Reforms In The UK